Abstract 1411P
Background
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression is often higher in malignant versus normal lung tissue. Tusamitamab ravtansine (tusa rav), an antibody-drug conjugate of humanized CEACAM5 antibody linked to cytotoxic DM4, showed promising antitumor activity and safety in heavily pretreated metastatic nonsquamous non-small cell lung cancer (mNSQ NSCLC) with high CEACAM5 expression. Docetaxel ± ramucirumab (ram) every 3 weeks is standard second-line therapy for mNSQ NSCLC without targetable mutations after progression on immunotherapy ± chemotherapy.
Methods
CARMEN-LC04 is an open-label phase 2 study (NCT04394624) assessing combination tusa rav 100 mg/m2 every 2 weeks (Q2W) + ram 8 mg/kg Q2W in patients with mNSQ NSCLC and high CEACAM5 expression (≥2+ intensity in ≥50% of tumor cells by immunohistochemistry). Patients had progression after an immune checkpoint inhibitor + platinum-based chemotherapy; patients with EGFR or BRAF mutations or ALK/ROS alterations had progression on targeted therapy. Primary endpoints were dose-limiting toxicity (DLT) in the first 4 weeks for Part 1 and objective response rate (ORR: confirmed complete response [CR] or partial response [PR]) per RECIST v1.1 for Part 2. Safety, disease control rate (DCR: CR + PR + stable disease), and progression-free survival (PFS) were assessed.
Results
As of April 2023, 31 total patients were treated in Parts 1 and 2. The median duration of exposure was 24.1 weeks (range, 3.9–106.0), with 6 (19.4%) patients still on treatment. No DLTs were observed (DLT-evaluable patients, n = 6). ORR was 19.4% (6/31) with 1 CR; DCR was 83.9% (26/31). Target lesion shrinkage occurred in 23/31 (74.2%) patients. Median PFS was 5.7 months (95% confidence interval, 5.4–9.1). Treatment-emergent adverse events (TEAEs) occurred in all patients; 12 (38.7%) patients had a Grade ≥3 TEAE. Seven (22.6%) patients had ≥1 corneal TEAEs: 5 (16.1%) Grade 2 and 2 (6.5%) Grade 3 as worst Grade. No treatment-emergent interstitial lung disease or toxic death was reported.
Conclusions
Tusa rav + ram showed encouraging efficacy. The safety of this combination was consistent with the safety profile of each drug, with no unexpected safety signals.
Clinical trial identification
NCT04394624.
Editorial acknowledgement
Medical writing assistance was provided by Micaela Genca, PharmD, inScience Communications, Springer Healthcare (Philadelphia, PA).
Legal entity responsible for the study
Sanofi, Inc.
Funding
Sanofi, Inc.
Disclosure
B.C. Cho: Financial Interests, Personal, Other, Consulting role: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus Therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen; Financial Interests, Personal, Advisory Board: Kanaph Therapeutic Inc, BridgeBio Therapeutics, Cyrus Therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Other, Advisory role: Medpacto, Blueprint medicines, RandBio, Hanmi; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, BridgeBio Therapeutics, Kanaph Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Institutional, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy, CJ Bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, BridgeBio Therapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center; Other, Founder: Daan Biotherapeutics. J. Oliveira: Financial Interests, Personal, Other, Advisory board, Invited speaker: AstraZeneca, Roche, Novartis, Janssen; Financial Interests, Personal, Invited Speaker: GSK, BMS, MSD, Bayer; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Institutional, Funding, Investigator Initiated Clinical Trial funding: AstraZeneca. L. Vila Martinez: Financial Interests, Personal, Advisory Board: Roche Pharma SA, Boehringer Ingelheim, AstraZeneca; Financial Interests, Personal, Research Funding: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, Merck, Roche Pharma. L. Charbonnier: Financial Interests, Personal, Full or part-time Employment: Sanofi; Financial Interests, Personal, Stocks/Shares: Sanofi. C. Soufflet: Financial Interests, Personal, Full or part-time Employment: Sanofi. J. de Castro Carpeño: Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Merck Sharp and Dohme, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20